OR WAIT null SECS
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
BioPharm International editors seek bioprocessing experts to contribute technical articles in 2017.
Although the calendar says October 2016, the editors of BioPharm International are thinking ahead to 2017. Our publishing schedule requires that we plan in advance, starting with a comprehensive editorial calendar for the coming year, and then looking at specific topics to cover in each month.
As part of this planning process, I invite bioprocessing experts to contribute to the print and online issues of BioPharm International. The editors welcome manuscripts on subjects pertinent to all aspects of biopharmaceutical drug development including upstream processing (protein expression, fermentation, and cell culture); downstream processing (separation and purification); manufacturing advances; formulation; drug delivery; quality and regulations; analytical technologies and methods; facilities design and expansion; supply chain and logistics; laboratory operations; and serialization/track and trace. The magazine also covers business topics such as sourcing and outsourcing; partnerships; intellectual property management; and economic development.
Both peer-review and technical article submissions are welcome. All submissions must be original, and cannot have been published previously in any format--including company literature or website postings--or any language. In addition, the articles must be objective and cannot promote a company’s products or services. Authors are expected to provide suitable references to published third-party literature to support all statements in submitted articles.
We seek manuscripts that offer technical and scientific discussions of ongoing drug development challenges and solutions, which are sufficiently novel to be of interest to an experienced audience. Topics should be timely and useful and should focus on the development of peptides, monoclonal antibodies, fusion proteins, other therapeutic proteins, nucleic acids, vaccines, cells for cell therapy, and any other class of biotechnologically generated molecular class.
Peer-review papers. Manuscripts submitted for peer review are double-blind reviewed by the publication’s editorial advisory board using procedures standard for scholarly and technical journals. Four types of peer-review submissions are considered: standard data-driven, novel research; technical case studies/application notes; topics literature or patent review; and science-based opinion paper. Accepted manuscripts are scheduled for publication in BioPharm International on a first-accepted basis.
Technical articles.BioPharm International accepts technical article contributions from scientific and technical experts from biopharmaceutical companies, academia, industry suppliers, and contract service organizations for publication in monthly issues, supplements, and as online articles. Articles related to topics listed on the BioPharm International 2017 editorial calendar are considered.
Submission guidelines. The editors have prepared guidelines for submission of peer-review papers, technical articles, and other contributions for publication in BioPharm International and on www.biopharminternational.com. The guidelines explain article rights, originality, and licensing; provide instructions for preparing an article for submission; list acceptable file types for figures, tables, and images; and include a style guide for references.
The BioPharm International Author’s Guidelines webpage explains the submission process, provides links to the editorial guidelines for peer-review and technical paper submissions, and contact information for authors. To access this information, visit www.biopharminternational.com and click the Author’s Guidelines link on the navigation menu. Of course, you can always reach me directly at firstname.lastname@example.org.
Vol. 29, No. 10
When referring to this article, please cite as R. Peters, "Calling All Authors," BioPharm International 29 (10) 2016.